Trial Profile
Effect of Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Locoregionally Advanced,Low-risk Nasopharyngeal Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Cis diamminediaquaplatinum; Cisplatin; Ropidoxuridine
- Indications Nasopharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Primary endpoint (5-year Overall Survival) has been met, according to a Simcere Pharmaceutical Group media release.
- 07 Jun 2022 According to a Simcere Pharmaceutical Group Media Release, data from this trial were presented at the 2022 annual meeting of American Society of Clinical Oncology (ASCO).